Chapters

Transcript

Video

ODYSSEY Outcomes reports that post-ACS patients with starting LDL-C levels greater than 100 mg/dL benefited most, but you have noted the importance of assessing “aggregate risk” when identifying triggers for PCSK9-based therapy. Can you discuss this?

ODYSSEY Outcomes reports that post-ACS patients with starting LDL-C levels greater than 100 mg/dL benefited most, but you have noted the importance of assessing “aggregate risk” when identifying triggers for PCSK9-based therapy. Can you discuss this?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Christian Ruff, MD

Christian Ruff, MD

Christian Ruff, MD
Principal Investigator, ENGAGE-AF Trial
TIMI Group
Director, General Cardiology
Brigham and Women’s Hospital
Assistant Professor of Medicine
Harvard Medical School
Boston, MA